GenScript expands capacity for cell and gene therapy programmes
Drug Discovery World
DECEMBER 23, 2022
GenScript USA has expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies. . The 400,000 square-foot cGMP facility enables gene and cell therapy R&D programmes to advance IND filings and clinical trials.
52 
Let's personalize your content